Johnson & Johnson Current Ratio 2010-2022 | JNJ

Current and historical current ratio for Johnson & Johnson (JNJ) from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Johnson & Johnson current ratio for the three months ending September 30, 2022 was 1.43.
Johnson & Johnson Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-09-30 $65.24B $45.54B 1.43
2022-06-30 $63.85B $44.82B 1.42
2022-03-31 $60.42B $43.39B 1.39
2021-12-31 $60.98B $45.23B 1.35
2021-09-30 $59.89B $44.56B 1.34
2021-06-30 $53.77B $38.72B 1.39
2021-03-31 $52.53B $40.93B 1.28
2020-12-31 $51.24B $42.49B 1.21
2020-09-30 $57.58B $38.85B 1.48
2020-06-30 $45.89B $36.77B 1.25
2020-03-31 $44.23B $33.69B 1.31
2019-12-31 $45.27B $35.96B 1.26
2019-09-30 $44.33B $35.16B 1.26
2019-06-30 $41.80B $31.35B 1.33
2019-03-31 $41.99B $29.11B 1.44
2018-12-31 $46.03B $31.23B 1.47
2018-09-30 $47.19B $27.44B 1.72
2018-06-30 $45.44B $27.49B 1.65
2018-03-31 $42.77B $27.08B 1.58
2017-12-31 $43.09B $30.54B 1.41
2017-09-30 $41.83B $31.81B 1.32
2017-06-30 $38.79B $28.87B 1.34
2017-03-31 $63.35B $25.12B 2.52
2016-12-31 $65.03B $26.29B 2.47
2016-09-30 $63.32B $23.23B 2.73
2016-06-30 $66.29B $21.54B 3.08
2016-03-31 $62.74B $22.13B 2.83
2015-12-31 $60.21B $27.75B 2.17
2015-09-30 $63.49B $25.26B 2.51
2015-06-30 $61.00B $24.51B 2.49
2015-03-31 $58.19B $23.84B 2.44
2014-12-31 $55.74B $25.03B 2.23
2014-09-30 $59.97B $22.98B 2.61
2014-06-30 $60.12B $24.36B 2.47
2014-03-31 $57.37B $23.84B 2.41
2013-12-31 $56.41B $25.68B 2.20
2013-09-30 $52.18B $25.84B 2.02
2013-06-30 $51.27B $23.77B 2.16
2013-03-31 $47.23B $22.52B 2.10
2012-12-31 $46.12B $24.26B 1.90
2012-09-30 $44.79B $23.94B 1.87
2012-06-30 $41.62B $23.85B 1.75
2012-03-31 $57.01B $21.20B 2.69
2011-12-31 $54.32B $22.81B 2.38
2011-09-30 $53.44B $21.69B 2.46
2011-06-30 $52.67B $20.99B 2.51
2011-03-31 $49.22B $24.01B 2.05
2010-12-31 $47.31B $23.07B 2.05
2010-09-30 $42.72B $17.41B 2.45
2010-06-30 $39.02B $17.16B 2.27
2010-03-31 $38.86B $18.50B 2.10
2009-12-31 $39.54B $21.73B 1.82
2009-09-30 $35.60B $19.25B 1.85
2009-06-30 $35.49B $19.89B 1.79
2009-03-31 $34.84B $21.33B 1.63
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $467.679B $93.775B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $356.089B 44.94
AbbVie (ABBV) United States $289.430B 12.00
Novo Nordisk (NVO) Denmark $287.171B 37.66
Pfizer (PFE) United States $285.774B 7.81
Merck (MRK) United States $278.995B 14.37
Novartis AG (NVS) Switzerland $199.112B 15.00